High molecular weight polysaccharide that binds and inhibits virus
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/353
A61K-031/70
A01N-043/04
A61K-036/87
A61K-009/00
A61K-031/715
C12N-007/00
G01N-033/569
출원번호
US-0107553
(2013-12-16)
등록번호
US-9707263
(2017-07-18)
발명자
/ 주소
Konowalchuk, Thomas W.
Konowalchuk, Jack
출원인 / 주소
WORLD FORCE TECHNOLOGIES, LLC
대리인 / 주소
Haliday, Emily M.
인용정보
피인용 횟수 :
1인용 특허 :
8
초록▼
This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibitin
This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
대표청구항▼
1. A pharmaceutical formulation in a delivery form selected from the group consisting of a tablet, a capsule, a lozenge, an ointment, a cream, a transdermal formulation, a gel, a nasal spray, a suppository, an injectable, and an implantable sustained-release formulation, wherein the pharmaceutical f
1. A pharmaceutical formulation in a delivery form selected from the group consisting of a tablet, a capsule, a lozenge, an ointment, a cream, a transdermal formulation, a gel, a nasal spray, a suppository, an injectable, and an implantable sustained-release formulation, wherein the pharmaceutical formulation comprises: a composition that binds to a virus and inhibits said virus, said composition comprising: an isolated polysaccharide comprising an arabinofuranosyl residue, a galactopyranosyl residue, and a galactouronic acid; anda catechin polymer;wherein said composition is soluble in water;wherein said composition is obtainable by a method comprising: preparing a substantially homogeneous aqueous mixture or solution of plant material from one or more plants of the Vitaceae family;contacting said mixture or solution with an ion exchange resin and recovering the colored product; andfurther purifying the colored product by removing components that can pass through a dialysis filter that generally passes molecules having a molecular weight of a 5×105 Daltons or less to produce said composition; andwherein said composition binds to a virus and reduces the infectivity or pathogenicity of said virus; anda pharmaceutically acceptable excipient; and wherein the said composition is formulated as a unit dosage formulation. 2. A pharmaceutical formulation in a delivery form selected from the group consisting of a tablet, a capsule, a lozenge, an ointment, a cream, a transdermal formulation, a gel, a nasal spray, a suppository, an injectable, and an implantable sustained-release formulation, wherein the pharmaceutical formulation comprises: a composition comprising: an isolated polysaccharide comprising an arabinofuranosyl residue, a rhamnopyranosyl residue, a galactopyranosyl residue, a glucopyranosyl residue, a mannopyranosyl residue, and a galactouronic acid; anda non-carbohydrate aromatic polymer;wherein said composition comprises about 40 to about 44 percent oxygen, about 44 to about 48 percent carbon, about 3 to about 6 percent hydrogen; and about 0.1 to about 1 percent nitrogen;wherein said composition is soluble in water;wherein said composition is obtainable by a method comprising: preparing a substantially homogeneous aqueous mixture or solution of plant material from one or more plants of the Vitaceae family;contacting said mixture or solution with an ion exchange resin and recovering the colored product; andfurther purifying the colored product by removing components that can pass through a dialysis filter that generally passes molecules having a molecular weight of a 5×105 Daltons or less to produce said composition; andwherein said composition binds to a virus and reduces the infectivity or pathogenicity of said virus; anda pharmaceutically acceptable excipient; andwherein the said composition is formulated as a unit dosage formulation. 3. The pharmaceutical formulation of claim 1, wherein the composition comprises about 10 to about 30 weight percent polysaccharide and about 70 to about 90 weight percent catechin polymer. 4. The pharmaceutical formulation of claim 1, wherein the composition comprises a component having a molecular weight greater than about 1 million Daltons. 5. The pharmaceutical formulation of claim 1, wherein the composition comprises a component having a molecular weight in the range of about 60,000 to about 100,000 Daltons. 6. The pharmaceutical formulation of claim 4, wherein the composition comprises an additional component having a molecular weight in the range of about 60,000 to about 100,000 Daltons. 7. The pharmaceutical formulation of claim 6, wherein the ratio of the amount of the component having a molecular weight greater than about 1 million Daltons to the amount of the component having a molecular weight in the range of about 60,000 to about 100,000 Daltons is about 95:5. 8. The pharmaceutical formulation of claim 1, wherein said composition does not comprise protein. 9. The pharmaceutical formulation of claim 1, wherein said polysaccharide comprises: about 30 to about 75 mole percent arabinose;about 0 to about 10 mole percent rhamnose;about 0 to about 5 mole percent xylose;about 0 to about 8 mole percent glucuronic acid;about 3 to about 36 mole percent galactouronic acid;about 0 to about 6 mole percent mannose;about 1 to about 20 mole percent galactose; andabout 0 to about 13 mole percent glucose. 10. The pharmaceutical formulation of claim 2, wherein said polysaccharide comprises: about 60 to about 66 mole percent arabinose;about 4.1 to about 4.5 mole percent rhamnose;about 2.2 to about 2.4 mole percent xylose;about 8.7 to about 9.7 mole percent galactouronic acid;about 2.3 to about 2.5 mole percent mannose;about 13.7 to about 15.1 mole percent galactose; andabout 4.2 to about 4.6 mole percent glucose. 11. The pharmaceutical formulation of claim 1, wherein said polysaccharide comprises: a terminally linked arabinofuranosyl residue (t-Araf);a 2-linked arabinofuranosyl residue (2-Araf);a 2-linked rhamnopyranosyl residue (2-Rhap);a 3-linked arabinofuranosyl residue (3-Araf);a terminally linked galactopyranosyl residue (t-Gal);a 5-linked arabinofuranosyl residue (5-Araf);a 3-linked glucopyranosyl residue (3-Glc) and/or a 2,4-linked rhamnopyranosyl residue (2,4-Rhap);a 2-linked glucopyranosyl residue (2-Glc);a 4-linked mannopyranosyl residue (4-Man);a 3,5-linked arabinofuranosyl residue (3,5-Araf);a 2,5-linked arabinofuranosyl residue (2,5-Araf);a 4-linked glucopyranosyl residue (4-Glc);a 2,3,5-linked arabinofuranosyl residue (3,5-Araf) and/or a 2,3,4-linked arabinopyranosyl residue (2,3,4-Arap);a 4-linked galactouronic acid (4-gal A);a 3,6-linked galactopyranosyl residue (3,6-Gal);a 2,3,4,6-linked mannopyranosyl residue (2,3,4,6-Man);a 2,3,4,6-linked galactopyranosyl residue (2,3,4,6-Gal)&2,3,4-linked galactouronic acid; anda 2,3,4,6-linked glucopyranosyl residue (2,3,4,6-Glc). 12. The pharmaceutical formulation of claim 11, wherein said polysaccharide comprises: said terminally linked arabinofuranosyl residue (t-Araf) comprises about 14.2 to about 15.7 wt percent of said polysaccharide;said 2-linked arabinofuranosyl residue (2-Araf) comprises about 9.1 to about 10.08 wt percent of said polysaccharide;said 2-linked rhamnopyranosyl residue (2-Rhap) comprises about 0.3 wt percent of said polysaccharide;said 3-linked arabinofuranosyl residue (3-Araf) comprises about 3.0 to about 3.4 wt percent of said polysaccharide;said terminally linked galactopyranosyl residue (t-Gal) comprises about 2.0 to about 2.2 wt percent of said polysaccharide;said 5-linked arabinofuranosyl residue (5-Araf) comprises about 15.0 to about 16.6 wt percent of said polysaccharide;said 3-linked glucopyranosyl residue (3-Glc) and/or 2,4-linked rhamnopyranosyl residue (2,4-Rhap) comprises about 0.7 wt percent of said polysaccharide;said 2-linked glucopyranosyl residue (2-Glc) comprises about 1.1 to about 1.3 wt percent of said polysaccharide;said 4-linked mannopyranosyl residue (4-Man) comprises about 1.3 to about 1.5 wt percent of said polysaccharide;said 3,5-linked arabinofuranosyl residue (3,5-Araf) comprises about 6.6 to about 7.3 wt percent of said polysaccharide;said 2,5-linked arabinofuranosyl residue (2,5-Araf) comprises about 5.0 to about 5.6 wt percent of said polysaccharide;said 4-linked glucopyranosyl residue (4-Glc) comprises about 4.6 to about 5.0 wt percent of said polysaccharide;said 2,3,5-linked arabinofuranosyl residue (3,5-Araf) and/or 2,3,4-linked arabinopyranosyl residue (2,3,4-Arap) comprises about 25.7 to about 28.4 wt percent of said polysaccharide;said 4-linked galactouronic acid (4-gal A) comprises about 1.4 to about 1.6 wt percent of said polysaccharide;said 3,6-linked galactopyranosyl residue (3,6-Gal) comprises about 0.4 wt percent of said polysaccharide;said 2,3,4,6-linked mannopyranosyl residue (2,3,4,6-Man) comprises about 0.7 wt percent of said polysaccharide;said 2,3,4,6-linked galactopyranosyl residue (2,3,4,6-Gal)&2,3,4-linked galactouronic acid comprises about 2.0 to about 2.2 wt percent of said polysaccharide; andsaid 2,3,4,6-linked glucopyranosyl residue (2,3,4,6-Glc) comprises about 2.1 to about 2.3 wt percent of said polysaccharide. 13. The pharmaceutical formulation of claim 1, wherein said composition binds a virus from a family selected from the group consisting of Adenoviridae, Picornaviridae, Reoviridae, Arenaviridae, Bunyaviridae, Coroanviridae, Herpesviridae, Orthomyxoviridae, Paramyxoviridae, Poxviridae Rhabdoviridae, Flaviviridae, and Retroviridae. 14. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a transdermal patch. 15. A method of inhibiting the infectivity and/or pathogenicity of a virus in a subject in a subject in need thereof, said method comprising administering to the subject an effective amount of a pharmaceutical formulation according to claim 1, wherein said effective amount is sufficient to inhibit infectivity and/or pathogenicity of the virus. 16. A method of inhibiting the growth and/or proliferation of a cancer cell in a subject in a subject in need thereof, said method comprising administering to the subject an effective amount of a pharmaceutical formulation according to claim 1, wherein said effective amount is sufficient to inhibit growth and/or proliferation of a cancer cell. 17. A method of ameliorating a symptom of aging in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical formulation according to claim 1, wherein said effective amount is sufficient to ameliorate a least one symptom of aging. 18. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a tablet. 19. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a capsule. 20. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a lozenge. 21. The pharmaceutical formulation of claim 1, wherein said composition is formulated in an ointment. 22. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a cream. 23. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a transdermal formulation. 24. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a gel. 25. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a nasal spray. 26. The pharmaceutical formulation of claim 1, wherein said composition is formulated in a suppository. 27. The pharmaceutical formulation of claim 1, wherein said composition is formulated in an injectable. 28. The pharmaceutical formulation of claim 1, wherein said composition is formulated in an implantable sustained-release formulation.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (8)
Umezawa Iwao (Tokyo JPX) Komiyama Kanki (Kanagawa JPX), Acidic polysaccharide CH-1 isolated from Chlorella pyrenoidosa and the use thereof.
Phalipon, Armelle; Sansonetti, Philippe; Felici, Franco; Cortese, Riccardo; Kraehenbuhl, Jean Pierre, Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions.
Masquelier Jack (Parc des Tourelles FRX), Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof.
Frangi Enrico (Milan ITX) Bertani Marco (Milan ITX) Mustich Giuseppe (Milan ITX) Tuccini Gianfranco (Milan ITX), Process for preparing grapeseed extracts enriched in procyanidol oligomers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.